师资队伍

邹争志，研究员，博士，博士生导师，硕士毕业于江西农业大学（导师黄路生院士），博士毕业于中山大学肿瘤防治中心分子医学专业（导师刘强教授）。现为中华医学会激光生物学分会青年委员、中国病理生理学会免疫专业委员会青年委员、广东省医学会老年免疫学会委员、广东省科技企业科技特派员。国家自然科学基金通讯评审专家、捷克和芬兰自然科学基金通讯评审专家、广东省自然科学基金通讯评审专家、广东省科技发展专项资金项目库专家。致力于肿瘤细胞生物学研究。近五年主持国家自然科学基金3项、广东省自然科学基金4项、广州市科技计划项目、广东省教育厅青年创新人才类项目1项和特色项目1项，作为骨干成员参与国家重大科研仪器专项，国家自然科学基金国际(地区)合作与交流项目、国家自然科学基金重点项目。申请发明专利7项，获发明专利3项。担任Frontiers in oncology客座主编。担任Science Advances、Autophagy、Oncogene、Journal of Hematology & Oncology等数十种TOP期刊审稿人。目前以第一作者或通讯作者在Acta Pharmaceutica Sinica B、Autophagy、Oncogene、Journal of Hematology & Oncology、Cell Death & Disease、Cancer letters 等杂志发表SCI文章35篇，第一作者或通讯作者文章他引次数6000多次，单篇最高600多次，3篇入选ESI高被引文章。文章总他引次数12000多次。文章被Nature reviews Molecular cell biology和Nature nanotechnology等顶级杂志多次引用。个人H-index 23。

近年主要代表作：

1. Yanlin Luo, Yibing Chen, Huan Jin, Benxin Hou, Hongsheng Li, Xiang Li, Lingfeng Liu, Yuan Zhou, Yonghua Li, Yong Sang Song, Quentin Liu, Zhengzhi Zou*. The suppression of cervical cancer ferroptosis by macrophages: the attenuation of ALOX15 in cancer cells by macrophages-derived exosomes. Acta Pharmaceutica Sinica B. 2023 (通讯作者，医学1区, IF: 14.903) doi.org/10.1016/j.apsb.2023.03.025

2 Jiajing Yan, Yibing Chen, Minhua Luo, Xinyu Hu, Hongsheng Li, Quentin Liu, Zhengzhi Zou*. Chronic stress in solid tumor development: from mechanisms to interventions. J Biomed Sci. 2023 Jan 28;30(1):8 (通讯作者, IF: 12.771，医学1区)

3.Huan Jin^#, Zhengzhi Zou^#, Haocai Chang, Qi Shen, Da Xing*. Photobiomodulation therapy for hair regeneration: A synergetic activation of β-CATENIN in hair follicle stem cells by ROS and paracrine WNTs. Stem cell reports. 2021 Jun 8;16(6):1568-1583. (共同第一，医学1区, IF: 7.765)   

4. Tang Q^#, Wang X^#, Jin H, Mi Y, Liu L, Dong M, Chen Y*, Zou Z*. Cisplatin-induced ototoxicity: updates on molecular mechanisms and otoprotective strategies. Eur J Pharm Biopharm. 2021 Jun;163:60-71. doi: 10.1016/j.ejpb.2021.03.008 (通讯作者, IF: 5.571，药学1区)

5. Haocai Chang and Zhengzhi Zou*. Targeting Autophagy to Overcome Drug Resistance: Further Developments. Journal of Hematology & Oncology. 2020. Nov (通讯作者, IF: 23.168，医学1区)

6. Ni Qiu, Yu-fang He, Si-ming Zhang, Yong-tao Zhan, Guo-dong Han, Ming Jiang, Wei-xing He, Jie Zhou, Hong-ling Liang, Xiang Ao, Hao-ming, Xia, Jia Li, Yu-yang Yang, Zhi-min He, Zhengzhi Zou*, Hong-sheng Li*. Cullin7 enhances resistance to trastuzumab therapy in Her2 positive breast cancer via degrading IRS-1 and downregulating IGFBP-3 to activate the PI3K/AKT pathway. Cancer Letters, 2019 Nov, 464: 25-36 (通讯作者, IF: 8.679，医学1区)

7. Chen Y, Mi Y, Zhang X, Ma Q, Song Y, Zhang L, Wang D, Xing J, Hou B, Li H, Jin H, Du W*, Zou Z*. Dihydroartemisinin-induced unfolded protein response feedback attenuates ferroptosis via PERK/ATF4/HSPA5 pathway in glioma cells. J. Exp. Clin. Cancer Res., 2019 Sep 13;38(1) DOI：10.1186/s13046-019-1413-7 (通讯作者, IF: 12.658，医学1区)

8. Yibing Chen^*, Yucen Song, Wei Du, Longlong Gong, Haocai Chang, Zhengzhi Zou^* Tumor-Associated Macrophages: an accomplice in solid tumor progression. Journal of biomedical science, 2019 Oct 20;26(1). (通讯作者, IF: 12.771，医学1区)

9. Songmao Wang, Zhengzhi Zou*, Haocai Chang and Da Xing*. LRH1 enhances breast cancer cells chemoresistance by activating MDC1 to attenuate DNA damage. Oncogene, 2018 Jun;37(24):3243-3259. doi: 10.1038/s41388-018-0193-4 (通讯作者, IF: 9.867，医学1区) 0950-9232

10. Chen P, Luo X, Nie P, Wu B, Xu W, Shi X, Chang H, Li B, Yu X, Zou Z*. CQ synergistically sensitizes human colorectal cancer cells to SN-38/CPT-11 through lysosomal and mitochondrial apoptotic pathway via p53-ROS cross-talk. Free Radic Biol Med, 2017 25;104:280-297. (通讯作者, IF: 8.101，医学1区) 0891-5849

11. Zhu J, Zou Z*, Nie P, Kou X, Wu B, Wang S, Song Z* and He J*. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression. Cell Death Dis., 2016;7:e2454. (共一兼通讯作者, IF: 9.685，医学1区)

12. Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S, Chang H, Zou Z*. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death Dis., 2016；7(11):e2463. doi: 10.1038/cddis.2016.367. (通讯作者, IF: 9.685，医学1区)

13. Qiao J#, Chen Y#, Mi Y#, Jin H#, Wang L, Huang T, Li H, Song Y, Cao J, Wu B, Wang Q*, Zou Z*. Macrophages confer resistance to BET inhibition in triple-negative breast cancer by upregulating IKBKE. Biochem. Pharmacol. 2020 Jun 27;180. (通讯作者, IF: 5.858, 药学2区)

14. Huan Jin^#, Wei Du^#, Wentao Huang, Jiajing Yan, Xiaorui An, Yibing Chen*, Zhengzhi Zou*, LncRNA and breast cancer: progresses from functional and regulatory mechanism to challenges and opportunities of clinical treatment. Molecular Therapy-Nucleic Acids，2021 Aug 19;25:613-637.（通讯作者，医学 2区, IF: 10.183)

15. Yonghua Li^#, Huan Jin^# (共一), Yibing Chen, Ting Huang, Wentao Huang, Yanjun Mi, Zhengzhi Zou*. Cancer cachexia: molecular mechanism and pharmacological management. Biochemical Journal 2021 May 14;478(9):1663-1688. doi: 10.1042/BCJ20201009  (通讯作者，生物学2区, IF: 3.857)

16. Kangkang Wang, Zhouyi Guo, Yang Li, Yanxian Guo, Hao Liu, Wen Zhang, Zhengzhi Zou,* Yanling Zhang, and Zhiming Liu*. Few-Layer NbTe2 Nanosheets as Substrates for Surface-Enhanced Raman Scattering Analysis. Acs Applied Nano Materials. 2020, 3, 11363−11371 (通讯作者, IF: 5.097，材料2区)

17. Chen Y, Jin H, Song Y, Huang T, Cao J, Tang Q, Zou Z*, Targeting tumor-associated macrophages: A potential treatment for solid tumors. J Cell Physiol., 2020 Nov 16：10.1002/jcp.30139 (通讯作者, IF: 6.384，生物2区)

18. Yibing Chen#*, Yucen Song#, Yanjun Mi#, Huan Jin, Jun Cao, Haolong Li, Liping Han, Ting Huang, Xiaofei Zhang, Lingyi Che, Zhihui Jiao, Shumin Ren, Qian Ma, Xu Gao, Zhengzhi Zou*. microRNA-499a promotes the progression and chemoresistance of cervical cancer cells by targeting SOX6. Apoptosis, 2020 05;25. (通讯作者, IF:4.677 生物2区)

19. Longlong Gong, Shuang Guo, Zhengzhi Zou* Resveratrol ameliorates metabolic disorders and insulin resistance in high-fat diet-fed mice. Life Sciences, 2019 Dec (通讯作者, IF: 6.78, 医学2区)

20. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. Apoptosis, 2017 Sep 21. doi: 10.1007/s10495-017-1424-9. (通讯作者, IF: 5.561，生物2区)

21. Liu L, Jin H, Dong M, Tian J, Li H, Liu Q, Chen Y, Zou Z*. Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. Apoptosis. 2022 Aug 26. doi: 10.1007/s10495-022-01766-5. (通讯作者, IF: 5.561，生物2区).

22.Minhua Luo, Jiajing Yan, Xinyu Hu, Haolong Li, Hongsheng Li, Quentin Liu, Yibing Chen, Zhengzhi Zou*. Targeting lipid metabolism for ferroptotic cancer therapy. Apoptosis, 2023 Feb;28(1-2):81-107. (通讯作者, IF: 5.561，生物2区).

1.国家自然科学基金-面上项目：乳腺癌化疗耐药细胞激活NCOA3促进巨噬细胞M2型极化诱导癌细胞转移的作用与机制。（81972479）直接经费：55万，主持 2020.01至2023.12

2.国家自然科学基金-面上项目：NR5A2上调MDC1促进DNA损伤修复增强乳腺癌化疗耐药研究（81772803）直接经费：60万，主持 2018.01至2021.12

3.雌激素诱导肿瘤相关巨噬细胞分泌装载SCAT1的外泌体促进宫颈癌转移的作用及机制。广东省自然科学基金面上项目。20万，主持 2024.01至2026.12

4.慢性应激促进乳腺癌转移的分子机制研究。华南肿瘤学国家重点实验室开放基金。5万，主持 2024.01 至 2025.12.31

5. 肿瘤相关巨噬细胞形成的微环境促进宫颈癌抵抗铁死亡机制研究。广东省自然科学基金面上项目(2021A1515012576)。10万，主持 2021.01至2023.12

6.MAPK4介导的巨噬细胞M2极化在宫颈癌恶性进展中的作用机制 广东省自然科学基金面上项目(2019A1515011100)。10万，主持 2019.10至2022.09

7. LRH1促进糖酵解增强NSCLC对EGFR-TKI耐药的研究 广州市科学研究计划一般项目（广州市科技计划项目-科学研究一般项目201904010038） 20万，主持 2019.04至2022.03

8.2021年广东省教育厅特色项目（自然科学类）：缺氧环境下肿瘤相关巨噬细胞促进三阴乳腺癌转移的作用与机制 6万，主持2022.01至2023.12

9.国家自然科学基金重大科研仪器研制项目：定量FRET显微成像仪的研制(61527825)，研究总经费510.32万元，直接经费442.1万元，起止年月：2016.01至2020.12 （参与，排名第三）